134 related articles for article (PubMed ID: 34628817)
21. Clinical Analysis of BRAF
Dong SY; Chen J; Xia EJ; Lin RX; Du HY; Wang OC; Zhang XH; Hao RT
Am Surg; 2020 May; 86(5):450-457. PubMed ID: 32684022
[TBL] [Abstract][Full Text] [Related]
22. Clinical Implication of Highly Sensitive Detection of the BRAFV600E Mutation in Fine-Needle Aspirations According to the Thyroid Bethesda System in Patients With Conventional Papillary Thyroid Carcinoma.
Seo JY; Choi JR; Moon HJ; Kim EK; Han KH; Kim H; Kwak JY
Ann Otol Rhinol Laryngol; 2015 May; 124(5):392-9. PubMed ID: 25404749
[TBL] [Abstract][Full Text] [Related]
23. Targeting Diagnosis of High-Risk Papillary Thyroid Carcinoma Using Ultrasound Contrast Agent With the BRAF
Xie F; Yan L; Li YM; Lan Y; Xiao J; Zhang MB; Jin Z; Zhang Y; Tian XQ; Zhu YQ; Li ZP; Luo YK
J Ultrasound Med; 2022 Nov; 41(11):2789-2802. PubMed ID: 35229905
[TBL] [Abstract][Full Text] [Related]
24. Real-Time PCR Cycle Threshold Values for the BRAFV600E Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis: A Retrospective Study.
Park VY; Kim EK; Lee HS; Moon HJ; Yoon JH; Kwak JY
Medicine (Baltimore); 2015 Jul; 94(28):e1149. PubMed ID: 26181555
[TBL] [Abstract][Full Text] [Related]
25. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
[TBL] [Abstract][Full Text] [Related]
26. mRNA BRAF expression helps to identify papillary thyroid carcinomas in thyroid nodules independently of the presence of BRAFV600E mutation.
Araujo PP; Marcello MA; Tincani AJ; Guilhen AC; Morari EC; Ward LS
Pathol Res Pract; 2012 Aug; 208(8):489-92. PubMed ID: 22770943
[TBL] [Abstract][Full Text] [Related]
27. Association analysis and the clinical significance of BRAF gene mutations and ultrasound features in papillary thyroid carcinoma.
Liu Y; He L; Yin G; Cheng L; Zeng B; Cheng J; Yang L
Oncol Lett; 2019 Sep; 18(3):2995-3002. PubMed ID: 31452778
[TBL] [Abstract][Full Text] [Related]
28. Association of BRAFV600E mutation with ultrasonographic features and clinicopathologic characteristics of papillary thyroid microcarcinoma: A retrospective study of 116 cases.
Chen B; Zhang Z; Wang K; Shang M; Zhao S; Ding W; Du R; Yu Z; Xu X
Clin Hemorheol Microcirc; 2019; 73(4):545-552. PubMed ID: 31306113
[TBL] [Abstract][Full Text] [Related]
29. Clinical Study of Ultrasonographic Risk Factors for Central Lymph Node Metastasis of Papillary Thyroid Carcinoma.
Guang Y; He W; Zhang W; Zhang H; Zhang Y; Wan F
Front Endocrinol (Lausanne); 2021; 12():791970. PubMed ID: 34917039
[TBL] [Abstract][Full Text] [Related]
30. BRAF V600E mutation and microRNAs are helpful in distinguishing papillary thyroid malignant lesions: Tissues and fine needle aspiration cytology cases.
Zarkesh M; Zadeh-Vakili A; Akbarzadeh M; Nozhat Z; Fanaei SA; Hedayati M; Azizi F
Life Sci; 2019 Apr; 223():166-173. PubMed ID: 30890403
[TBL] [Abstract][Full Text] [Related]
31. Role of ultrasonographic features and quantified BRAFV600E mutation in lymph node metastasis in Chinese patients with papillary thyroid carcinoma.
Guo L; Ma YQ; Yao Y; Wu M; Deng ZH; Zhu FW; Luo YK; Tang J
Sci Rep; 2019 Jan; 9(1):75. PubMed ID: 30635590
[TBL] [Abstract][Full Text] [Related]
32. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
Kim SK; Song KH; Lim SD; Lim YC; Yoo YB; Kim JS; Hwang TS
Thyroid; 2009 Feb; 19(2):137-41. PubMed ID: 19014278
[TBL] [Abstract][Full Text] [Related]
33. The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC.
Park VY; Kim EK; Moon HJ; Yoon JH; Kwak JY
Medicine (Baltimore); 2016 Jul; 95(29):e4292. PubMed ID: 27442672
[TBL] [Abstract][Full Text] [Related]
34. Ultrasound validation of predictive model for central cervical lymph node metastasis in papillary thyroid cancer on
Chen J; Li XL; Zhang YF; Wang D; Wang Q; Zhao CK; Li MX; Wei Q; Ji G; Xu HX
Future Oncol; 2020 Aug; 16(22):1607-1618. PubMed ID: 32501726
[No Abstract] [Full Text] [Related]
35. Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma.
Kim YS; Kim JS; Bae JS; Park WC
World J Surg Oncol; 2013 May; 11():99. PubMed ID: 23687957
[TBL] [Abstract][Full Text] [Related]
36. Radiomics Study of Thyroid Ultrasound for Predicting
Kwon MR; Shin JH; Park H; Cho H; Hahn SY; Park KW
AJNR Am J Neuroradiol; 2020 Apr; 41(4):700-705. PubMed ID: 32273326
[TBL] [Abstract][Full Text] [Related]
37. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
38. Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis.
Kim WW; Ha TK; Bae SK
J Otolaryngol Head Neck Surg; 2018 Jan; 47(1):4. PubMed ID: 29316976
[TBL] [Abstract][Full Text] [Related]
39. Differential diagnosis of diffuse sclerotic thyroid papillary carcinoma and Hashimoto's thyroiditis using fine-needle aspiration cytology, BRAF
Wang X; Xu F; Gao J; Agyekum EA; Sun H; Zhang G; Li X; Xiang H; Hu S; Qian X
J Clin Ultrasound; 2022 Sep; 50(7):942-950. PubMed ID: 35779272
[TBL] [Abstract][Full Text] [Related]
40. Conventional Ultrasound, Immunohistochemical Factors and BRAF
Chen J; Li XL; Zhao CK; Wang D; Wang Q; Li MX; Wei Q; Ji G; Xu HX
Ultrasound Med Biol; 2018 Nov; 44(11):2296-2306. PubMed ID: 30100099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
